BAP Council Member Details

Council Member

Dr Michael Browning

Michael Browning

University of Oxford
Council Member until 2021

The BAP fulfils a unique role in the UK. Its annual conference is the key national forum in which biological psychiatric research is presented, meaning that it is the best place to present your own work and to find out what others in your area are doing. Its educational program, which includes clinical masterclasses and the preclinical psychopharmacology course, provides evidence based information for both clinicians and preclinical scientists. Lastly, the BAP’s pubic engagement activities help to promote a balanced understanding of the role of psychopharmacology. As a result, the BAP has become an essential component in supporting and encouraging the development of young researchers and in representing psychopharmacology at the national level.

Over the many years I have been a member of the BAP it has supported me to attend oversees conferences as well as providing a national platform to present my work. More importantly than this, most of the researchers and research active clinicians I know in the UK I have met at the BAP conference.

I am a clinical researcher with a specific interest in the emotional disorders and the mechanisms by which the treatments of these illnesses exert their effects. I am based in the Department of Psychiatry in Oxford. My current research includes both mechanistic and treatment development studies. As well as working in the NHS and academia I have previously worked in industry and so have broad experience of both psychopharmacology research as well as the ultimate clinical application of that research.

While on the council I will work 1) to support the development of early career researchers (both financially and professionally), 2) to support the translation of academic research into tangible gains for patients (via liaison with industry and engagement with clinicians and patients) and 3) to provide clear unbiased information on the pros and cons of psychopharmacological treatments to the public and the media.

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. I own shares in P1vital Products Ltd
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. I am employed (0.5 days/week) by P1vital Ltd
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. I have acted as a consultant for J&J
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. No
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. No
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. No
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. No
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. I have recruited patients for studies sponsored by J&J
  21. If there is anything else you feel it necessary to disclose, please provide details below:

Form completed on 5th September 2018